** Buy-now-pay-later (BNPL) firm Afterpay APT.AX is
heading for third straight session of losses, its longest run in
over two months
** APT down 1.6% to A$94.41, having fallen as much as 3%
earlier
** Promising news from separate COVID-19 vaccine trials by
Pfizer PFE.N and Moderna MRNA.O has halted charge of one of
pandemic's stand-out stocks
** This week also saw Australian regulator call out the
sector on number of missed payments by users, though refrained
for asking for regulation urn:newsml:reuters.com:*:nL1N2I20HV
** APT is down nearly 9% so far this week, having climbed
more than 10 times since March
** Smaller rivals Zip Co Ltd Z1P.AX , Sezzle SZL.AX and
Laybuy Holdings LBY.AX also fell between 0.5% and 1.7%
** At its AGM on Tuesday, APT said November was tracking
ahead of record underlying sales in October in a
seasonally-strong quarter
(Reporting by Nikhil Kurian Nainan)
((NikhilKurian.Nainan@thomsonreuters.com; Twitter:
@NikhilKurianN))